{"id":2336,"date":"2026-07-27T11:57:31","date_gmt":"2026-07-27T11:57:31","guid":{"rendered":"https:\/\/naturalhealthcontent.com\/index.php\/2026\/07\/27\/crystalys-therapeutics-investit-130-millions-de-dollars-pour-des-tests-pivots-sur-un-medicament-contre-la-goutte\/"},"modified":"2026-07-27T11:57:31","modified_gmt":"2026-07-27T11:57:31","slug":"crystalys-therapeutics-investit-130-millions-de-dollars-pour-des-tests-pivots-sur-un-medicament-contre-la-goutte","status":"publish","type":"post","link":"https:\/\/naturalhealthcontent.com\/index.php\/2026\/07\/27\/crystalys-therapeutics-investit-130-millions-de-dollars-pour-des-tests-pivots-sur-un-medicament-contre-la-goutte\/","title":{"rendered":"Crystalys Therapeutics investit 130 millions de dollars pour des tests pivots sur un m\u00e9dicament contre la goutte"},"content":{"rendered":"

Crystalys Therapeutics is moving forward with plans to potentially launch its gout medication, dotinurad, despite not yet having pivotal trial data. This ambitious strategy is bolstered by a recent $130 million Series B financing<\/a> announced last Wednesday.<\/p>\n

This new funding comes less than a year after the company’s launch, which brought a candidate gout drug under license and a significant $205 million Series A investment. Crystalys, based in San Diego, has since advanced dotinurad into two Phase 3 studies, paving the way for a potential FDA approval application, in addition to an ongoing Phase 2 study.<\/p>\n

The three trials aim to assess the investigational drug in a diverse patient population suffering from gout. Beyond merely funding clinical trials, the company stated that the new capital will facilitate regulatory milestones and commercialization preparations.<\/p>\n

Gout is characterized by elevated uric acid levels in the blood, leading to crystal formation in joints and surrounding tissues, which causes inflammation and joint pain. Dotinurad functions as a small molecule URAT1 inhibitor, targeting a protein that leads to uric acid reabsorption in the kidneys.<\/p>\n

“By blocking the transporter, you effectively excrete more uric acid,” explained CEO James Mackay last year during an interview regarding the company launch.<\/p>\n

Crystalys holds the rights to dotinurad for the United States and select global markets through a licensing agreement with Urica Therapeutics. Urica obtained these rights from Fuji Yakuhin, the Japanese company that discovered and developed dotinurad. Urica also retains an equity stake in the biotechnology firm, along with a 3% royalty on sales of any approved product in the designated markets, according to regulatory documents. Outside of Japan, dotinurad is already commercially available in certain Asian markets.<\/p>\n

Gout affects millions, yet pharmaceutical innovation in this area has been limited. The standard treatment is allopurinol, a medication that has been in use for decades, designed to inhibit an essential enzyme involved in uric acid production. However, many patients find this approach inadequate. Amgen\u2019s Krystexxa, an enzyme-based treatment for refractory cases of gout, is available as a third-line option. A second-line drug from Takeda Pharmaceutical, however, was withdrawn earlier this year due to cardiovascular concerns.<\/p>\n

The URAT1 inhibition mechanism is gaining traction as a promising approach for second-line gout treatment. In December, Swedish Orphan Biovitrum (Sobi) acquired Arthrosi Therapeutics for $950 million, gaining access to pozdeutinurad, an advanced URAT1 inhibitor currently in development. In May, Sobi reported preliminary Phase 3 results<\/a> indicating that both tested doses achieved the primary endpoint of reducing uric acid levels after six months compared to a placebo. These studies are ongoing for a full year, and the daily pill has been well tolerated with a safety profile consistent with prior studies. Detailed results from these trials are expected to be presented at a scientific meeting in Q4 of this year.<\/p>\n

Frazier Life Sciences led the Series B financing for Crystalys, with several participants in the round being crossover investors supporting both private and public firms. Such funding often signals that a company is preparing for an initial public offering. When asked via email if the recent financing indicated a crossover round, Mackay noted, “We are keeping all our financing options open at this time.”<\/p>\n

Other participants in the funding round included Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Trails Edge Capital Partners, Pivotal bioVenture Partners, and KCap Biotechnology Fund. Previously involved investors include Novo Holdings, SR One, Catalys Pacific, Perceptive Xontogeny Venture Funds, Lightstone Ventures, AN Venture Partners, funds managed by abrdn Inc., KB Investments, Pontifax, Longwood Fund, Alexandria Venture Investments, Wedbush Healthcare Partners, and Prebys Ventures Fund.<\/p>\n

Illustration: Kateryna Kon\/Scientific Photo Library, via Getty Images<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Crystalys Therapeutics is moving forward with plans to potentially launch its gout medication, dotinurad, despite…<\/p>\n","protected":false},"author":1,"featured_media":2337,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[19],"tags":[],"class_list":["post-2336","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma"],"_links":{"self":[{"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/posts\/2336","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/comments?post=2336"}],"version-history":[{"count":1,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/posts\/2336\/revisions"}],"predecessor-version":[{"id":2338,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/posts\/2336\/revisions\/2338"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/media\/2337"}],"wp:attachment":[{"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/media?parent=2336"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/categories?post=2336"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/tags?post=2336"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}